IR information

I would like to express my sincere gratitude to all our shareholders and investors for your continued support and encouragement. We have received many messages expressing confidence in Kitazato, and we are truly grateful for your trust. We remain dedicated to tackling the challenges of the declining birthrate and becoming a world-leading company from Japan.

Globally, the fields of obstetrics, gynecology, and fertility treatment are advancing to meet growing patient needs, while also contributing to societal efforts to address declining birthrates. In Japan, insurance coverage for fertility treatment began in 2022, and the number of patients has been on the rise. Worldwide, many countries including China have launched national initiatives to tackle the declining birthrate, and the global market continues to expand.

We are currently receiving multiple proposals for joint research and development from leading scientists. This year, we established a new research institute to further strengthen our R&D capabilities. By proactively investing in research to improve fertility treatment and by continuously driving product innovation, we aim to achieve sustainable growth and enhance corporate value, while contributing to a society where every child can grow up in health and well-being.

Now, our sales and profits continue to grow steadily. With a clear focus on improving operating margins and increasing the proportion of overseas sales as our management goals, Kitazato remains committed to advancing our business initiatives. I sincerely ask for your continued support and encouragement as we move forward together.

November 2025
Futoshi INOUE
President and CEO